Table 2

Differences in treatment regimens and outcomes between the non-MNV group and subsequent MNV group

Non-MNV group
(n=153)
Subsequent MNV group
(n=23)
P value
Follow-up period (months)30.0±16.232.8±17.50.602*
Treatment regimens0.163
PDT, n (%)89 (58.2)15 (65.2)
PDT alone, n (%)77 (50.3)10 (43.5)
PDT+anti-VEGF, n (%)2 (1.3)1 (4.3)
PDT+focal laser, n (%)10 (6.5)4 (17.4)
Focal laser, n (%)38 (24.8)2 (8.7)
Anti-VEGF, n (%)2 (1.3)1 (4.3)
Total recurrence, n (%)59 (38.6)14 (60.9)0.043†
Within the first year, n (%)30 (19.6)9 (39.1)0.104†‡
After the first year, n (%)29 (19.0)5 (21.7)1.000†‡
Final BCVA, logMAR
 (Snellen)
0.02±0.27
(20/21)
0.15±0.22
(20/28)
<0.001*
Incomplete resolution on final OCT, n (%)48 (31.4)17 (73.9)<0.001†
SRF, n (%)19 (12.4)8 (34.8)0.002‡
PED, n (%)23 (15.0)3 (13.0)1.000‡
SRF+PED, n (%)1 (0.7)6 (26.1)<0.001‡
Macular oedema, n (%)5 (3.3)01.000‡
  • Values are the mean±SD or n (%).

  • *Statistical analysis with the Mann-Whitney U test.

  • †Statistical analysis with Fisher’s exact test or Pearson’s χ2 test.

  • ‡Bonferroni-adjusted p values.

  • anti-VEGF, anti-vascular endothelial growth factor; BCVA, best-corrected visual acuity; logMAR, logarithm of the minimum angle of resolution; MNV, macular neovascularisation; OCT, optical coherence tomography; PDT, photodynamic therapy; PED, pigment epithelial detachment; SRF, subretinal fluid.